Sustained-release pharmaceutical composition containing acebrophylline and hydrophobic sustained-release agent

A kind of technology of bromoacetphylline and composition, applied in the field of sustained-release pharmaceutical composition, can solve the problems such as patient's pain, inability to achieve therapeutic effect, irregular administration time and the like

Active Publication Date: 2016-08-03
HYUNDAI PHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Bromacetophylline preparations that have been approved in Korea, for example, a product called surfolase (Modern Drugs) can be taken twice a day and 100 mg each time, when combined with a drug that is taken once a day or a drug that is taken once a day When comparing the medicines of three times (before and after meals), there are the following problems: the patient's medication compliance is lowered because the time point of administration is not clear, and the administration time (interval) is not specified, so the desired...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained-release pharmaceutical composition containing acebrophylline and hydrophobic sustained-release agent
  • Sustained-release pharmaceutical composition containing acebrophylline and hydrophobic sustained-release agent
  • Sustained-release pharmaceutical composition containing acebrophylline and hydrophobic sustained-release agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Preparation of Hydrophobic Sustained Release Formulations Comprising Ethylcellulose

[0060] The ingredients 1 to 4 of Table 1 were mixed and granulated, respectively. Components 5 to 7 in Table 1 were added to the granulated granules, mixed, and tabletted. After tableting, coating was performed with the coating agent No. 8 in Table 1.

[0061] Table 1

[0062]

Embodiment 2

[0063] Example 2: Preparation of Hydrophobic Sustained Release Formulations Comprising Waxes

[0064] The ingredients of 1 to 4 in Table 2 were mixed and granulated, respectively. Components 5 to 6 in Table 2 were added to the granulated granulated product, mixed, and tabletted. After tableting, coating was performed with the coating agent 7 in Table 2.

[0065] Table 2

[0066]

Embodiment 3

[0067] Example 3: Preparation of Hydrophobic Sustained Release Formulation Containing Monoglyceryl Behenate

[0068] The ingredients 1 to 4 of Table 3 were mixed and granulated, respectively. Components 5 to 6 in Table 3 were added to the granulated granulated product, mixed, and tabletted. After tableting, the coating agent 7 in Table 3 was used for coating.

[0069] table 3

[0070]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition containing acebrophylline thereby having both immediate and extended release characteristics, and more specifically, to a sustained-release pharmaceutical composition containing acebrophylline and a hydrophobic sustained-release agent.

Description

technical field [0001] The invention relates to a sustained-release pharmaceutical composition comprising bromacetate theophylline and a hydrophobic sustained-release agent. Background technique [0002] Acebrophylline (acebrophylline) is a compound synthesized by using 7-theophylline to salify ambroxol (ambroxol). It is a salt composed of an acid and a base. When administered orally, Separation into ambroxol and 7-theophylline for metabolism. Bromoacetate theophylline selectively acts on the bronchi and lung tissue to inhibit the activity of phospholipase in the bronchoalveolar and increase the surface activity of the alveoli, thereby exerting an expectorant effect. In addition, by inhibiting the formation of leukotrienes (LTs) and prostaglandins (PGs), it exerts an efficient anti-inflammatory effect, so by reducing bronchial hypersensitivity, it restores the contracted bronchi to a normal state or dilates them. [0003] Bromacetophylline preparations that have been appro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/22A61K9/28A61K47/38A61K31/522
CPCA61K31/137A61K31/519A61K9/2027A61K9/209A61K9/2866A61P11/00A61P11/02A61P11/06A61P11/10A61K2300/00A61K9/20A61K9/28A61K47/38A61K31/522
Inventor 李丰奭李忠烈金声延李东日尹旻祉
Owner HYUNDAI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap